Merck’s myeloid data add support for the emerging target class
Merck strengthens oncology pipeline beyond Keytruda with a trio of ESMO readouts
Merck’s cancer pipeline beyond Keytruda strengthens with a trio of ESMO presentations spanning myeloid targets, next-generation checkpoints and first-in-class molecules.
The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy may complement checkpoint inhibition.
At the European Society of Medical Oncology (ESMO) Virtual Congress, Merck & Co. Inc. (NYSE:MRK) presented initial data from a Phase I trial of its anti-ILT4 mAb MK-4830, showing that the first-in-class